

No association between common variations in the human alpha 2 subunit gene (ATP1A2) of the sodium–potassium-transporting ATPase and idiopathic generalized epilepsy

Falk W. Lohoff^{a,b,*}, Thomas N. Ferraro^a, Thomas Sander^b, Hongyu Zhao^c,
John P. Dahl^a, Wade H. Berrettini^a, Russell J. Buono^{a,d}

^a Department of Psychiatry, University of Pennsylvania School of Medicine, Center for Neurobiology and Behavior,
3535 Market Street, 2nd Floor, R2070, Philadelphia, PA 19104, USA

^b Department of Neurology, Charité University Medicine Berlin, Germany

^c Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

^d Department of Neurology, University of Cincinnati, OH, USA

Received 23 November 2004; received in revised form 21 January 2005; accepted 24 February 2005

Abstract

Quantitative trait loci studies in inbred mice have identified a locus on chromosome 1 (*Szs1*) of fundamental importance to seizure susceptibility. High-ranking candidate genes in this susceptibility region include *KCNJ9*, *KCNJ10* and *ATP1A2*. We performed a systematic mutation scan of the coding region of the human *ATP1A2* gene and performed a case–control association study with seven common markers. Genotypes were assessed in 152 idiopathic generalized epilepsy (IGE) patients of German ancestry and 111 healthy German controls for all seven polymorphisms. No significant differences were found in genotype or allele frequencies for any of the variations between the IGE patients and controls. No haplotypes were associated with IGE when compared to controls. Linkage disequilibrium was demonstrated throughout the gene. Results suggest that the polymorphisms we studied in the *ATP1A2* gene do not represent major susceptibility factors for common forms of IGE.

© 2005 Elsevier Ireland Ltd. All rights reserved.

Keywords: Na–K-ATPase; Seizure; DNA polymorphism; Genetics; Association

Hereditary factors play a predominant role in the etiology of idiopathic generalized epilepsy (IGE), which accounts for 30% of all epilepsies [9,15,34]. However, genetic causes of the common IGE syndromes are difficult to identify due to the complex mode of inheritance and genetic heterogeneity [22,28,38].

In our laboratory we use a polygenic mouse model to identify genes which influence seizure susceptibility. Quantitative trait loci (QTL) mapping and congenic animal studies with inbred mice, which display focal and generalized seizures depending on the used seizure induction method [10,12,13], have led to the identification of a critical region on distal mouse chromosome 1 (*Szs1*) which harbors

a gene or genes that contribute to both generalized and focal seizure susceptibility [10–13]. High priority candidate genes in this seizure susceptibility region and the homologous human region (1q21–23) include *KCNJ9*, *KCNJ10* and *ATP1A2* [4,11].

Several lines of evidence make *ATP1A2* a plausible candidate for an IGE susceptibility gene. The sodium–potassium pump is involved in regulation of ion homeostasis across the cell membrane and several rare forms of epilepsy are caused by mutations in genes controlling ion homeostasis [38]. Recently, mutations in the *ATP1A2* gene were shown to cause familial hemiplegic migraine (FHM) [1,7,21,36,39]. Interestingly, members of two families had benign familial infantile convulsions [40] or generalized seizures [36] in addition to hemiplegic migraine episodes [19]. Further studies in patients with epilepsy and experimental animal

* Corresponding author. Tel.: +1 215 746 7229; fax: +1 215 573 2041.
E-mail address: lohoff@mail.med.upenn.edu (F.W. Lohoff).

models suggest a relationship between Na–K-pump activity and seizures [18,20,23,24,27,30,33]. Mutations in the ATP1A2 gene may cause seizures given the fundamental role of the ATPase enzyme in regulating neuronal membrane potential and hence neuronal firing [17,25,26,35].

In this study we performed a systematic mutation scan of the ATP1A2 coding region and tested the hypothesis that common variations in the ATP1A2 gene confer susceptibility to IGE.

IGE patients were collected at the Department of Neurology, Charité University Medicine Berlin, Germany. The study protocol was approved by the Institutional Ethics Committee. Written informed consent was obtained from all participants who were unrelated individuals of German descent. The study sample included 152 IGE patients, comprising 37 probands with childhood absence epilepsy (CAE), 32 probands with juvenile absence epilepsy (JAE), and 83 probands with juvenile myoclonic epilepsy (JME). The diagnostic classification of IGE syndromes was performed according to the revised version of the ‘Classification of Epilepsies and Epileptic Syndromes’ of the International League Against Epilepsy [6]. Diagnostic criteria for JME were: (a) characteristic repetitive bilateral myoclonic jerks in shoulders and arms without loss of consciousness, occurring after awakening; (b) age-of-onset of typical myoclonic seizures between 8 and 25 years. Diagnostic criteria for idiopathic absence epilepsy (CAE or JAE) were: (a) begin with typical absence seizures (brief spells of generalized onset with loss of consciousness); (b) age at onset of typical absence seizures between 3 and 20 years. Common inclusion criteria were: (a) EEG with normal background activity and paroxysmal GSW–EEG discharges; (b) normal intellectual and neurological status beside seizures. General exclusion criteria included: (a) evidence for structural lesions, metabolic or degenerative diseases of the brain; (b) atonic/astatic or tonic seizures; (c) complex partial seizures; (d) epilepsy with myoclonic absences; (e) exclusively stimulus induced seizures.

The population controls included 111 healthy German individuals with no history of seizures or chronic neurological disease.

Peripheral blood samples were obtained and genomic DNA was extracted from peripheral leukocytes by standard procedures.

The ATP1A2 gene consists of 23 exons and spans about 26 kb (NCBI Access # J05096). Review of the public database, the Celera database and the literature revealed one synonymous single nucleotide polymorphism (SNP) in the coding region of the ATP1A2 gene and at least 91 non-coding SNPs. Several missense mutations have been reported in patients with FHM [1,7,21,36,39].

All 23 exons and intron–exon boundaries were systematically screened for mutations in 30 individuals with epilepsy and 30 controls using single strand conformation polymorphism (SSCP) analysis as described [2]. Details of intron–exon structure and primer sequences are available upon request. PCR conditions, genotyping and primer pairs for the intron 1 ins-6704/TTCC variation were described previously [3]. All SNPs were confirmed by subcloning and sequencing PCR amplicons from at least three separate PCR reactions from different individuals.

The intron 1 ins-6704/TTCC and intron 22 variations were genotyped using SSCP analysis. The exon 9 SNP introduced a *DdeI* restriction site allowing genotyping by standard agarose gel electrophoresis and ethidium bromide staining of the restriction fragment length polymorphism (RFLP).

Additional SNPs for genotyping were chosen based on availability of *Applied Biosystems* assays-on-demand, location in the gene and allele frequencies. Genotyping of four additional intronic SNPs across the ATP1A2 gene (Fig. 1) was performed using the *Applied Biosystems* ‘‘Assays-on-demand’’ SNP genotyping assay as per manufacturers protocol (C_7479749_10/rs1016732, C_1843218_10/rs1407130, C_1843220_10/rs6686067, C_15867718_10/rs2070702).

Genotypes and allele frequencies were compared between groups using chi-square contingency analysis. A two-tailed type I error rate of 5% was chosen for the analysis. No correction for multiple testing was made based on the rationale that this is an explorative approach to a genetically complex disorder in which a phenotype–genotype relationship has not been established [32]. Our sample size had reasonable power to detect a disease association at a *P*-value less than or equal to 0.05, assuming a genetic effect of 2.0 (Table 1). Power analysis was performed using the *Quanto* program [16]. Linkage disequilibrium (LD) was calculated using the *2ld* program [41]. Haplotype frequencies were estimated using the *EH* program [29] and *Cocaphase* program [8].




Fig. 1. Variations in the ATP1A2 gene.

Table 4
Analysis of common haplotypes in the ATP1A2 gene

Haplotype	Case	Frequency	Control	Frequency	OR	Chi-square	P
G(-)-C-G-C-C-G	85.78	0.373	56.85	0.400	1.0	0.360	0.548
G(-)-C-G-C-C-C	15.60	0.067	15.72	0.110	0.657	1.881	0.170
G(-)-C-G-C-T-G	40.87	0.177	23.17	0.163	1.169	0.104	0.746
G(-)-C-A-C-C-G	8.93	0.038	5.88	0.041	1.005	0.010	0.917
G(-)-T-G-C-C-C	17.33	0.075	10.74	0.075	1.07	0.014	0.996
G-TTCC-C-G-C-C-C	2.18	0.009	3.10	0.021	0.466	0.713	0.398
G-TTCC-C-A-C-C-C	26.63	0.115	13.61	0.095	1.297	0.256	0.612
A(-)-T-G-T-C-G	32.68	0.142	12.94	0.091	1.674	2.111	0.146

Association studies are a powerful method to detect genes that are involved in the etiology of complex traits like epilepsy [22]. In particular, association studies are most powerful when a pathophysiological plausible candidate gene is examined and a functional polymorphism is studied that itself might mediate the predisposing effect. In this study we systematically screened the coding region for mutations and selected common polymorphism across the ATP1A2 gene for a case–control association study.

The 4-bp insertion in intron 1 is located in the polypyrimidine tract preceding immediately exon 2. Disruption of this critical sequence, which is important for proper mRNA splicing, by the ins-6704/TTCC polymorphism could therefore directly lead to an altered mRNA and potential protein dysfunction and expression. However, this polymorphism was previously investigated in a small case–control association study using temporal lobe epilepsy patients and controls and was not associated with illness [3]. It is unlikely that the intronic polymorphisms or the silent polymorphisms in exon 9 themselves are involved in the etiology of IGE, unless they are in regulatory or splice junction sites, but they could be in LD with another variation which influences seizure threshold. LD is the central concept of association studies. LD between SNPs is unlikely to extend beyond an average distance of approximately 10 kb [31] and our marker spacing was sufficient to detect LD (Fig. 1 and Table 3); however, the extent of LD varies in different genomic regions and limited information is available about the characteristics of LD within candidate genes.

We observed no difference in allele frequencies of variations or common haplotypes in the ATP1A2 gene between IGE and controls, and demonstrated strong LD throughout the gene thus reducing the likelihood that variants in the coding, promoter or 3'-untranslated region are associated with illness. Our mutation screening did not reveal any missense mutations in the coding region; however, the number of IGE patients and controls was small. Additional analysis of sequence variations in epilepsy cases might be necessary in order to detect rare variations affecting illness [5].

Although the sample size may not be sufficient to detect small or rare allelic effects, there was no indication for a trend towards statistical significance and we had reasonable power

to detect moderate genetic effects (Table 1). Larger sample sizes in the thousands are required for future studies of genes with small effects. Population stratification is unlikely to play a relevant confounding role in this population since all cases and controls were of German descent; however, case–control association studies of subjects with self-reported ancestries are not immune to population stratification [14]. A more accurate control would be the use of a family-based association design that matches the genotype of an affected offspring with those parental alleles not inherited by the offspring [37].

In summary, we showed that common variations in the ATP1A2 gene are not associated with epilepsy in this group of IGE patients and controls.

Acknowledgements

This work was supported by the Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania. Financial support is gratefully acknowledged from National Institutes of Health grants R01 NS40396 (to R.J.B.) and R25 MH060490 (to F.W.L.) and a grant from the Deutsche Forschungsgemeinschaft (Sa434/3-1 to T.S.). F.W. Lohoff received a scholarship from Charité University Medicine Berlin, Germany.

References

- [1] M.T. Bassi, N. Bresolin, A. Tonelli, K. Nazos, F. Crippa, C. Baschiroto, C. Zucca, A. Bersano, D. Dolcetta, F.M. Boneschi, V. Barone, G. Casari, A novel mutation in the ATP1A2 gene causes alternating hemiplegia of childhood, *J. Med. Genet.* 41 (2004) 621–628.
- [2] W.H. Berrettini, J. Vuoristo, T.N. Ferraro, R.J. Buono, D. Wildenauer, L. Ala-Kokko, Human G(olf) gene polymorphisms and vulnerability to bipolar disorder, *Psychiatr. Genet.* 8 (1998) 235–238.
- [3] R.J. Buono, T.N. Ferraro, M.J. O'Connor, M.R. Sperling, M. Abbey, E. Finanger, F. Lohoff, N. Mulholland, W.H. Berrettini, Lack of association between temporal lobe epilepsy and a novel polymorphism in the alpha 2 subunit gene (ATP1A2) of the sodium potassium transporting ATPase, *Am. J. Med. Genet.* 96 (2000) 79–83.

- [4] R.J. Buono, F.W. Lohoff, T. Sander, M.R. Sperling, M.J. O'Connor, D.J. Dlugos, S.G. Ryan, G.T. Golden, H. Zhao, T.M. Scattergood, W.H. Berrettini, T.N. Ferraro, Association between variation in the human KCNJ10 potassium ion channel gene and seizure susceptibility, *Epilepsy Res.* 58 (2004) 175–183.
- [5] J.C. Cohen, R.S. Kiss, A. Pertsemelidis, Y.L. Marcel, R. McPherson, H.H. Hobbs, Multiple rare alleles contribute to low plasma levels of HDL cholesterol, *Science* 305 (2004) 869–872.
- [6] Commission on Classification and Terminology of the International League Against Epilepsy, Proposal for revised classification of epilepsies and epileptic syndromes, *Epilepsia*, 30 (1989) 389–399.
- [7] M. De Fusco, R. Marconi, L. Silvestri, L. Atorino, L. Rampoldi, L. Morgante, A. Ballabio, P. Aridon, G. Casari, Haploinsufficiency of ATP1A2 encoding the Na⁺/K⁺ pump alpha2 subunit associated with familial hemiplegic migraine type 2, *Nat. Genet.* 33 (2003) 192–196.
- [8] F. Dudbridge, Pedigree disequilibrium tests for multilocus haplotypes, *Genet. Epidemiol.* 25 (2003) 115–121.
- [9] A.D. Everitt, J.W. Sander, Classification of the epilepsies: time for a change? A critical review of the International Classification of the Epilepsies and Epileptic Syndromes (ICEES) and its usefulness in clinical practice and epidemiological studies of epilepsy, *Eur. Neurol.* 42 (1999) 1–10.
- [10] T.N. Ferraro, G.T. Golden, G.G. Smith, R.L. Longman, R.L. Snyder, D. DeMuth, I. Szpilzak, N. Mulholland, E. Eng, F.W. Lohoff, R.J. Buono, W.H. Berrettini, Quantitative genetic study of maximal electroshock seizure threshold in mice: evidence for a major seizure susceptibility locus on distal chromosome 1, *Genomics* 75 (2001) 35–42.
- [11] T.N. Ferraro, G.T. Golden, G.G. Smith, J.F. Martin, F.W. Lohoff, T.A. Gieringer, D. Zamboni, C.L. Schwebel, D.M. Press, S.O. Kratzer, H. Zhao, W.H. Berrettini, R.J. Buono, Fine mapping of a seizure susceptibility locus on mouse Chromosome 1: nomination of *Kcnj10* as a causative gene, *Mamm. Genome* 15 (2004) 239–251.
- [12] T.N. Ferraro, G.T. Golden, G.G. Smith, N.J. Schork, P. St Jean, C. Ballas, H. Choi, W.H. Berrettini, Mapping murine loci for seizure response to kainic acid, *Mamm. Genome* 8 (1997) 200–208.
- [13] T.N. Ferraro, G.T. Golden, G.G. Smith, P. St Jean, N.J. Schork, N. Mulholland, C. Ballas, J. Schill, R.J. Buono, W.H. Berrettini, Mapping loci for pentylenetetrazol-induced seizure susceptibility in mice, *J. Neurosci.* 19 (1999) 6733–6739.
- [14] M.L. Freedman, D. Reich, K.L. Penney, G.J. McDonald, A.A. Mignault, N. Patterson, S.B. Gabriel, E.J. Topol, J.W. Smoller, C.N. Pato, M.T. Pato, T.L. Petryshen, L.N. Kolonel, E.S. Lander, P. Sklar, B. Henderson, J.N. Hirschhorn, D. Altshuler, Assessing the impact of population stratification on genetic association studies, *Nat. Genet.* 36 (2004) 388–393.
- [15] C.M. Freitag, T.W. May, M. Pfafflin, S. Konig, D. Rating, Incidence of epilepsies and epileptic syndromes in children and adolescents: a population-based prospective study in Germany, *Epilepsia* 42 (2001) 979–985.
- [16] W.J. Gauderman, Sample size requirements for association studies of gene-gene interaction, *Am. J. Epidemiol.* 155 (2002) 478–484.
- [17] S.M. Gloor, Relevance of Na⁺/K⁺-ATPase to local extracellular potassium homeostasis and modulation of synaptic transmission, *FEBS Lett.* 412 (1997) 1–4.
- [18] D. Guillaume, T. Grisar, A.V. Delgado-Escueta, M. Bureau-Heeren, J. Laschet, Phosphorylation of brain (Na⁺,K⁺)-ATPase alpha catalytic subunits in normal and epileptic cerebral cortex: I. The audiogenic mice and the cat with a freeze lesion, *J. Neurosci. Res.* 29 (1991) 207–217.
- [19] E. Gutierrez-Delgado, J.M. Serratos, Genetics of the epilepsies, *Curr. Opin. Neurol.* 17 (2004) 147–153.
- [20] T.C. Kang, S.K. Park, I.K. Hwang, S.J. An, M.H. Won, Altered Na⁺-K⁺ ATPase immunoreactivity within GABAergic neurons in the gerbil hippocampal complex induced by spontaneous seizure and vigabatrin treatment, *Neurochem. Int.* 45 (2004) 179–187.
- [21] M.A. Kaunisto, H. Harno, K.R. Vanmolkot, J.J. Gargus, G. Sun, E. Hamalainen, E. Liukkonen, M. Kallela, A.M. van den Maagdenberg, R.R. Frants, M. Farkkila, A. Palotie, M. Wessman, A novel missense ATP1A2 mutation in a Finnish family with familial hemiplegic migraine type 2, *Neurogenetics* 5 (2004) 141–146.
- [22] E.S. Lander, N.J. Schork, Genetic dissection of complex traits, *Science* 265 (1994) 2037–2048.
- [23] J. Laschet, D. Guillaume, T. Grisar, M. Vergnolle-Burette, A. Minet, Effect of milacemide on audiogenic seizures and cortical (Na⁺,K⁺)-ATPase of DBA/2J mice, *Epilepsia* 32 (1991) 151–156.
- [24] G.J. Lees, Inhibition of sodium-potassium-ATPase: a potentially ubiquitous mechanism contributing to central nervous system neuropathology, *Brain Res. Rev.* 16 (1991) 283–300.
- [25] J. Lingrel, A. Moseley, I. Dostanic, M. Coughnon, S. He, P. James, A. Woo, K. O'Connor, J. Neumann, Functional roles of the alpha isoforms of the Na₂K-ATPase, *Ann. N. Y. Acad. Sci.* 986 (2003) 354–359.
- [26] J.B. Lingrel, T. Kuntzweiler, Na⁽⁺⁾,K⁽⁺⁾-ATPase, *J. Biol. Chem.* 269 (1994) 19659–19662.
- [27] A.E. Moseley, S.P. Lieske, R.K. Wetzel, P.F. James, S. He, D.A. Shelly, R.J. Paul, G.P. Boivin, D.P. Witte, J.M. Ramirez, K.J. Sweadner, J.B. Lingrel, The Na₂K-ATPase alpha 2 isoform is expressed in neurons, and its absence disrupts neuronal activity in newborn mice, *J. Biol. Chem.* 278 (2003) 5317–5324.
- [28] J.L. Noebels, The biology of epilepsy genes, *Annu. Rev. Neurosci.* 26 (2003) 599–625.
- [29] J. Ott, Analysis of Human Genetic Linkage, Johns Hopkins University Press, 1999.
- [30] S.T. Palayoor, T.N. Seyfried, Genetic study of cationic ATPase activities and audiogenic seizure susceptibility in recombinant inbred and congenic strains of mice, *J. Neurochem.* 42 (1984) 529–533.
- [31] N. Patil, A.J. Berno, D.A. Hinds, W.A. Barrett, J.M. Doshi, C.R. Hacker, C.R. Kautzer, D.H. Lee, C. Marjoribanks, D.P. McDonough, B.T. Nguyen, M.C. Norris, J.B. Sheehan, N. Shen, D. Stern, R.P. Stokowski, D.J. Thomas, M.O. Trulson, K.R. Vyas, K.A. Frazer, S.P. Fodor, D.R. Cox, Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21, *Science* 294 (2001) 1719–1723.
- [32] T.V. Perneger, What's wrong with Bonferroni adjustments, *Br. Med. J.* 316 (1998) 1236–1238.
- [33] K. Renkawek, W.O. Renier, J.J. de Pont, O.J. Vogels, F.J. Gabreels, Neonatal status convulsivus, spongiform encephalopathy, and low activity of Na⁽⁺⁾/K⁽⁺⁾-ATPase in the brain, *Epilepsia* 33 (1992) 58–64.
- [34] T. Sander, The genetics of idiopathic generalized epilepsy: implications for the understanding of its aetiology, *Mol. Med. Today* 2 (1996) 173–180.
- [35] L. Segall, R. Scanzano, M.A. Kaunisto, M. Wessman, A. Palotie, J.J. Gargus, R. Blostein, Kinetic alterations due to a missense mutation in the Na₂K-ATPase alpha 2 subunit cause familial hemiplegic migraine type 2, *J. Biol. Chem.* (2004).
- [36] M. Spadaro, S. Ursu, F. Lehmann-Horn, V. Liana, A. Giovanni, G. Paola, M. Frontali, K. Jurkat-Rott, A G301R Na⁽⁺⁾/K⁽⁺⁾-ATPase mutation causes familial hemiplegic migraine type 2 with cerebellar signs, *Neurogenetics* (2004).
- [37] R.S. Spielman, W.J. Ewens, The TDT and other family-based tests for linkage disequilibrium and association, *Am. J. Hum. Genet.* 59 (1996) 983–989.
- [38] O.K. Steinlein, Genetic mechanisms that underlie epilepsy, *Nat. Rev. Neurosci.* 5 (2004) 400–408.
- [39] K.J. Swoboda, E. Kanavakis, A. Xaidara, J.E. Johnson, M.F. Leppert, M.B. Schlesinger-Massart, L.J. Ptacek, K. Silver, S. Youroukos, Alternating hemiplegia of childhood or familial hemiplegic migraine? A novel ATP1A2 mutation, *Ann. Neurol.* 55 (2004) 884–887.
- [40] K.R. Vanmolkot, E.E. Kors, J.J. Hottenga, G.M. Terwindt, J. Haan, W.A. Hoefnagels, D.F. Black, L.A. Sandkuijl, R.R. Frants, M.D. Fer-

rari, A.M. van den Maagdenberg. Novel mutations in the Na⁺,K⁺-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions, *Ann. Neurol.* 54 (2003) 360–366.

[41] C. Zapata, C. Carollo, S. Rodriguez, Sampling variance and distribution of the D' measure of overall gametic disequilibrium between multiallelic loci, *Ann. Hum. Genet.* 65 (2001) 395–406.